Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor

IT-901 is a novel and selective NF-κB inhibitor with promising activity in pre-clinical models. Here we show that treatment of chronic lymphocytic leukemia cells (CLL) with IT-901 effectively interrupts NF-κB transcriptional activity. CLL cells exposed to the drug display elevated mitochondrial reac...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaisitti, Tiziana, Gaudino, Federica, Ouk, Samedy, Moscvin, Maria, Vitale, Nicoletta, Serra, Sara, Arruga, Francesca, Zakrzewski, Johannes L., Liou, Hsiou-Chi, Allan, John N., Furman, Richard R., Deaglio, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664392/
https://www.ncbi.nlm.nih.gov/pubmed/28860341
http://dx.doi.org/10.3324/haematol.2017.173419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664392/
https://www.ncbi.nlm.nih.gov/pubmed/28860341
http://dx.doi.org/10.3324/haematol.2017.173419

Ejemplares similares